Vistagen Therapeutics

Vistagen Therapeutics is a late clinical-stage neuroscience company based in South San Francisco, California, developing rapid-onset intranasal product candidates known as pherines for psychiatric and neurological disorders. Its lead asset fasedienol (PH94B) nasal spray is in Phase 3 development for the acute treatment of social anxiety disorder; the PALISADE-4 Phase 3 trial did not meet its endpoints in June 2026, and in September 2026 the company reported preliminary positive data from the study's open-label extension and said it plans to meet the FDA during the current quarter on the path forward. The company's pherine portfolio also includes itruvone (PH10) for major depressive disorder, refisolone (PH80), AV-101, PH15 and PH284. Founded in 1998, the company has operated as Vistagen Therapeutics since its 2023 rebrand from VistaGen Therapeutics and trades on the Nasdaq Capital Market.